| Year |
Title |
Altmetric |
| 2021
|
Targeting the HuR oncogenic role with a new class of cytoplasmic dimerization inhibitors..
Cancer Research.
2021
|
|
| 2020
|
Elavl1 role in cell fusion and tunneling membrane nanotube formations with implication to treat glioma heterogeneity.
Cancers.
12:1-18.
2020
|
|
| 2020
|
Seven-Year Experience from the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical Trials.
JAMA Neurology.
77:755-763.
2020
|
|
| 2020
|
Rindopepimut with bevacizumab for patients with relapsed EGFRvIII-expressing glioblastoma (REACT): Results of a double-blind randomized phase II trial.
Clinical Cancer Research.
26:1586-1594.
2020
|
|
| 2020
|
Glioma risk associated with extent of estimated European genetic ancestry in African Americans and Hispanics.
International Journal of Cancer.
146:739-748.
2020
|
|
| 2020
|
An update on neurofibromatosis type 1-associated gliomas.
Cancers.
12.
2020
|
|
| 2019
|
Anti-cancer effects of the HuR inhibitor, MS-444, in malignant glioma cells.
Cancer Biology and Therapy.
20:979-988.
2019
|
|
| 2019
|
An early feasibility study of the Nativis Voyager ® device in patients with recurrent glioblastoma: first cohort in US.
CNS Oncology.
8:CNS30.
2019
|
|
| 2019
|
MGMT promoter methylation cutoff with safety margin for selecting glioblastoma patients into trials omitting temozolomide: A pooled analysis of four clinical trials.
Clinical Cancer Research.
25:1809-1816.
2019
|
|
| 2019
|
Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma..
Clinical Cancer Research.
25:73-79.
2019
|
|
| 2018
|
Results of phase II trial of SL-701, a novel immunotherapy targeting IL-13Ra2, EphA2, and survivin, in adults with second-line recurrent glioblastoma (GBM).
Annals of Oncology.
29:viii122-viii123.
2018
|
|
| 2018
|
Associations of anticoagulant use with outcome in newly diagnosed glioblastoma.
European journal of cancer.
101:95-104.
2018
|
|
| 2018
|
Toenail selenium, genetic variation in selenoenzymes and risk and outcome in glioma
2018
|
|
| 2018
|
Activation of the receptor tyrosine kinase AXL regulates the immune microenvironment in glioblastoma.
Cancer Research.
78:3002-3013.
2018
|
|
| 2017
|
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.
Cancer Chemotherapy and Pharmacology.
80:1209-1217.
2017
|
|
| 2017
|
Hu antigen R (HuR) multimerization contributes to glioma disease progression.
Journal of Biological Chemistry.
292:16999-17010.
2017
|
|
| 2017
|
Older age at the completion of linear growth is associated with an increased risk of adult glioma.
Cancer Causes and Control.
1-8.
2017
|
|
| 2016
|
Primary Sellar Rhabdomyosarcoma Arising in Association with a Pituitary Adenoma.
International Journal of Surgical Pathology.
24:753-756.
2016
|
|
| 2016
|
Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, with temozolomide (TMZ) in recurrent glioblastoma (rGBM).
Annals of Oncology.
27:vi103.
2016
|
|
| 2016
|
Analgesic use and the risk of primary adult brain tumor.
European Journal of Epidemiology.
31:917-925.
2016
|
|
| 2016
|
Design of a Phase i Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma
2016
|
|
| 2016
|
Complications from pharmacotherapy.
Handbook of Clinical Neurology.
134:235-250.
2016
|
|
| 2015
|
Ipilimumab-induced encephalopathy with a reversible splenial lesion.
Cancer Immunology Research.
3:598-601.
2015
|
|
| 2015
|
Growth factor dependent regulation of centrosome function and genomic instability by HuR.
Biomolecules.
5:263-281.
2015
|
|
| 2015
|
Brain tumor risk according to germ-line variation in the MLLT10 locus.
European Journal of Human Genetics.
23:132-134.
2015
|
|
| 2014
|
Circadian pathway genes in relation to glioma risk and outcome.
Cancer Causes and Control.
25:25-32.
2014
|
|
| 2014
|
The role of Src family kinases in growth and migration of glioma stem cells.
International Journal of Oncology.
45:302-310.
2014
|
|
| 2013
|
Toenail iron, genetic determinants of iron status, and the risk of glioma.
Cancer Causes and Control.
24:2051-2058.
2013
|
|
| 2013
|
Early life exposures and the risk of adult glioma.
European Journal of Epidemiology.
28:753-758.
2013
|
|
| 2013
|
Anthropometric factors in relation to risk of glioma.
Cancer Causes and Control.
24:1025-1031.
2013
|
|
| 2013
|
SWI/SNF gene variants and glioma risk and outcome
2013
|
|
| 2013
|
A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma.
Clinical Cancer Research.
19:900-908.
2013
|
|
| 2012
|
A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306).
Cancer.
118:5601-5607.
2012
|
|
| 2012
|
Erratum: An exploratory analysis of common genetic variants in the vitamin D pathway including genome-wide associated variants in relation to glioma risk and outcome (Cancer Causes Control DOI:10.1007/s10552-012-0018-7).
Cancer Causes and Control.
23:1745.
2012
|
|
| 2012
|
Phosphoregulation of the RNA-binding protein Hu antigen R (HuR) by Cdk5 affects centrosome function.
Journal of Biological Chemistry.
287:32277-32287.
2012
|
|
| 2012
|
SSBP2 variants are associated with survival in glioblastoma patients.
Clinical Cancer Research.
18:3154-3162.
2012
|
|
| 2012
|
An exploratory analysis of common genetic variants in the vitamin D pathway including genome-wide associated variants in relation to glioma risk and outcome.
Cancer Causes and Control.
23:1443-1449.
2012
|
|
| 2011
|
Cilengitide: An RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies.
Future Oncology.
7:339-354.
2011
|
|
| 2010
|
Integrins-a relevant target in glioblastoma.
European journal of clinical & medical oncology.
2.
2010
|
|
| 2010
|
Rationally designed pharmacogenomic treatment using concurrent capecitabine and radiotherapy for glioblastoma; gene expression profiles associated with outcome.
Clinical Cancer Research.
16:2890-2898.
2010
|
|
| 2010
|
Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.
Clinical Cancer Research.
16:2443-2449.
2010
|
|
| 2010
|
A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma.
Archives of Neurology.
67:313-319.
2010
|
|
| 2009
|
Amyotrophic lateral sclerosis-linked mutant SOD1 sequesters Hu antigen R (HuR) and TIA-1-related protein (TIAR). Implications for impaired post-transcriptional regulation of vascular endothelial growth factor.
Journal of Biological Chemistry.
284:33989-33998.
2009
|
|
| 2009
|
Isolated central nervous system posttransplant lymphoproliferative disorder treated with high-dose intravenous methotrexate.
American Journal of Transplantation.
9:1243-1248.
2009
|
|
| 2008
|
Cilengitide: An integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme.
Expert Opinion on Investigational Drugs.
17:1225-1235.
2008
|
|
| 2008
|
Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: Implications for STAT-3 activation and gene expression.
Clinical Cancer Research.
14:4694-4704.
2008
|
|
| 2007
|
ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis.
Cancer Biology and Therapy.
6:454-462.
2007
|
|
| 2006
|
Case report of a patient with primary central nervous system lymphoma treated with radioimmunotherapy
2006
|
|
| 2006
|
Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: Results of North Central Cancer Treatment Group protocol N0177
2006
|
|
| 2005
|
Lyn kinase activity is the predominant cellular Src kinase activity in glioblastoma tumor cells.
Cancer Research.
65:5535-5543.
2005
|
|
| 2005
|
Treatment of adults with recurrent malignant glioma
2005
|
|
| 2005
|
IL-1β induces stabilization of IL-8 mRNA in malignant breast cancer cells via the 3′ untranslated region: Involvement of divergent RNA-binding factors HuR, KSRP and TIAR.
International Journal of Cancer.
113:911-919.
2005
|
|
| 2004
|
Treatment of relapsed central nervous system lymphoma with high-dose methotrexate.
Clinical Cancer Research.
10:5643-5646.
2004
|
|
| 2004
|
Targeted molecular therapy for malignant gliomas.
Current Treatment Options in Oncology.
5:519-526.
2004
|
|
| 2003
|
Tumor necrosis factor α induces angiogenic factor up-regulation in malignant glioma cells: A role for RNA stabilization and HuR.
Cancer Research.
63:4181-4187.
2003
|
|
| 2002
|
Human cytomegalovirus infection and expression in human malignant glioma.
Cancer Research.
62:3347-3350.
2002
|
|
| 2001
|
HuR, a RNA stability factor, is expressed in malignant brain tumors and binds to adenine- and uridine-rich elements within the 3′ untranslated regions of cytokine and angiogenic factor mRNAs.
Cancer Research.
61:2154-2161.
2001
|
|
| 2000
|
Analysis of the 5' end of the mouse Elavl1 (mHuA) gene reveals a transcriptional regulatory element and evidence for conserved genomic organization.
Gene.
242:125-131.
2000
|
|
| 1999
|
Hu antigen specificities of ANNA-I autoantibodies in paraneoplastic neurological disease.
Journal of Autoimmunity.
13:435-443.
1999
|
|
